Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the University of Pennsylvania, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Inovio Pharmaceuticals Inc.

Virgin Wines UK PLC ( ($GB:VINO) ) has shared an announcement. Virgin Wines UK PLC has announced the posting of its Annual Report & Accounts for th...

Virgin Wines UK PLC Releases Annual Report for 2025

Virgin Wines UK PLC ( ($GB:VINO) ) has shared an announcement. Virgin Wines UK PLC has announced its upcoming Annual General Meeting and General Me...

Virgin Wines UK PLC Seeks Approval for Share Buyback and Rule 9 Waiver

Barclays analyst Theresa Chen maintained a Hold rating on HF Sinclair Corporation today and set a price target of $54.00. Chen covers the Energy se...

HF Sinclair Corporation (DINO) Gets a Hold from Barclays

The recent pullback in tech has rattled nerves, but so far it looks more like a dip than a meaningful setback. The NASDAQ is only 4.5% off its late...

‘Mini Panic’ Moment in Tech Won’t Last, Says Daniel Ives — Here Are 2 Tech Stocks He Likes Right Now

Virgin Wines UK PLC ( ($GB:VINO) ) has shared an update. Virgin Wines UK PLC has executed a share buyback program, purchasing 103,320 ordinary shar...

Virgin Wines Executes Share Buyback Program

In a report released today, Hartaj Singh from Oppenheimer maintained a Buy rating on Inovio Pharmaceuticals, with a price target of $13.00. Accordi...

Inovio Pharmaceuticals (INO) Receives a Buy from Oppenheimer

Innodata Isogen ( ($INOD) ) has released its Q3 earnings. Here is a breakdown of the information Innodata Isogen presented to its investors. Innoda...

Innodata Isogen Reports Strong Revenue Growth

There’s a lot to be optimistic about in the Energy sector as 2 analysts just weighed in on HF Sinclair Corporation (DINO – Research Report) and Dia...

Analysts’ Top Energy Picks: HF Sinclair Corporation (DINO), Diamondback (FANG)

Hino Motors ( ($JP:7205) ) just unveiled an announcement. Hino Motors has announced a significant step in its business integration with Mitsubishi ...

Hino Motors and Mitsubishi Fuso Announce Formation of ARCHION Corporation

In a report released today, Paul Cheng from Scotiabank maintained a Buy rating on HF Sinclair Corporation, with a price target of $66.00. The compa...

Scotiabank Keeps Their Buy Rating on HF Sinclair Corporation (DINO)

Analysts have been eager to weigh in on the Technology sector with new ratings on Innodata (INOD – Research Report) and KLA (KLAC – Research Report...

Current Quarter	$-0.41	Next Quarter	$-0.42
Current Year	$-1.99	Next Year	$-1.44
QoQ Growth	-2.4%	YoY Growth	+27.6%
3Y EPS CAGR	+39.0%	Target Price	$7.47
Consensus	Buy	Upside	+324.4%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	INO	$1.76	+1.73%	755.11K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	INO	$1.76	+1.7%	755.11K
3
4
5
6

INO

INO

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Inovio Pharmaceuticals Inc. Data in Excel

Get Inovio Pharmaceuticals Inc. Data in Excel